Sunglow Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 19 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Ebitda
- Net Worth -109.08%
- Total Assets %
About Sunglow Pharma
Sunglow Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 May 2005 and has a history of 19 years and eight months. Its registered office is in Na, Telangana.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Prem Raj, Prem Aailaboyina, Smitha Aailaboyina, and Two other members serve as directors at the Company.
Company Details
-
LocationNa, Telangana
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24239TG2005PTC046351
-
Company No.
046351
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
26 May 2005
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Sunglow Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prem Raj
|
Managing Director | 26-May-2005 | Current |
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Prem Aailaboyina
|
Director | 26-May-2005 | Current |
|
Smitha Aailaboyina
|
Director | 26-May-2005 | Current |
|
Sai Nama
|
Director | 26-May-2005 | Current |
|
Chandra Nama
|
Director | 26-May-2005 | Current |
Financial Performance of Sunglow Pharma.
Sunglow Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 109.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sunglow Pharma?
In 2016, Sunglow Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sunglow Pharma?
Unlock and access historical data on people associated with Sunglow Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sunglow Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sunglow Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.